

Special Issue

Radiation Therapy for Breast Cancer: Recent Advances and Challenges

Message from the Guest Editor

In recent years, new technological developments have been applied in breast irradiation aiming at reducing the doses to organs at risk while maintaining optimal doses to the breast and lymph node bearing areas. Axillary irradiation has become an alternative to surgery in many patients with positive sentinel lymph nodes, in the context of surgical de-escalation. In selected patients, hypofractionation with increased dose per fraction and decreased irradiated volume has allowed the development of partial breast irradiation as an alternative to standard radiotherapy, resulting in reduced costs and increased quality of life. Research in the field of individual patients' radiosensitivity will hopefully provide a better selection of irradiation schemes adapted individually to each patient. All these advances and challenges will be addressed in our Special Issue, which will provide answers to many pending questions in the new era of breast cancer radiotherapy.

Guest Editor

Prof. Dr. Yazid Belkacémi

1. INSERM 955 EQ07, The Mondor Institute for Biomedical Research (IMRB), University of Paris-Est Creteil (UPEC), Créteil, France
2. Department of Radiation Oncology, Henri Mondor University Hospital & Henri Mondor Breast Cancer Center, 94000 Créteil, France

Deadline for manuscript submissions

closed (31 January 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/72795

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)